Quantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets Built

Key Points

• AI is accelerating drug discovery, but clinical trial requirements continue to shape biotech investment risks.
• Quantum BioPharma's Anthony Durkacz sees Phase 2 results, competition, and cash runway as major considerations for biotech investors.
• Quantum BioPharma is preparing a Phase 2 multiple sclerosis trial, with Durkacz expecting topline data in 2027.

Artificial intelligence (AI) is compressing parts of drug discovery from years into, in some cases, minutes. The regulatory clock has not sped up to match.

That gap is where biotech investors win or lose. A lab breakthrough is still only a candidate until it clears human trials overseen by the U.S. Food and Drug Administration (FDA), and small biotech stocks tend to trade on where a drug sits in that process rather than how exciting the science sounds.

More AI-powered discovery could also mean more companies, more trials, and more biotech stocks chasing the same pool of capital. Sorting the contenders from the long shots starts with knowing which phase carries which risk.

A trial phase says less about the science than about the odds, the waiting period and how much dilution may still be coming.

AI Speeds Discovery, But FDA Phase Trials Still Set the Pace

Anthony Durkacz, co-founder and executive co-chairman of the board at Quantum BioPharma NASDAQ: QNTM, calls AI the most exciting technical development the industry has seen. In his view, the technology could generate more and better drug development data in minutes than the field has produced in centuries.

Regulators still control the gate, and for good reason. Protocols exist because safety comes first.

Phase 1 tests safety and tolerability, typically in healthy volunteers. Phase 2 moves the drug into patients with the target disease to look for efficacy. Phase 3 widens the pool for more data before a drug can be submitted for regulatory approval.

Timelines vary by drug and target. Durkacz puts the floor at roughly three to four years from the start of Phase 1, with fast-track and compassionate-use pathways available for diseases where patients have no other options.

Phase 2 Data Is Where Biotech Value Tends to Get Built

The odds at the starting line are brutal. Fewer than 3% of drugs entering Phase 1 become approved products, according to an estimate Durkacz cited from an industry conference.

Phase 1 investors also face the longest wait and the highest chance of another capital raise, which can dilute existing shareholders well before any payoff arrives.

Positive Phase 2 data changes the math. By his estimate, roughly 90% of drugs that reach Phase 3 go on to commercialization, though strong early results still don't guarantee a Phase 3 pass.

That matters because of who shows up next. Big pharma partnerships are rare in Phase 1, occasionally appear after Phase 2 and most often arrive at Phase 3, when the largest drugmakers would rather pay up than shoulder early research and development (R&D) risk. Some well-funded biotechs push through Phase 3 alone to keep more of the royalties.

Market Size, Competition, and Cash Runway Separate Contenders From Long Shots

Science alone doesn't make an investment. Durkacz flags the addressable market as critical, since a drug needs a large enough patient base to make economic sense.

Crowding is the other filter. Five companies chasing the same mechanism of action would concern him. A unique approach to an unmet need with little or no competition carries more weight.

Then comes cash. A company that starts a trial without the money to finish it risks delays and dilutive raises. Funding through the next data readout is often the clearest line between a contender and a long shot.

A Small-Cap Multiple Sclerosis Program Moves Into Phase 2

Quantum BioPharma is preparing to begin a Phase 2 trial in multiple sclerosis (MS) and recently announced it is working with Thermo Fisher Scientific NYSE: TMO, which Durkacz credits with deep experience in these types of trials.

Here's where it gets interesting. Current MS drugs target the immune system and, at best, slow progression. Quantum BioPharma's candidate aims to help patients regain control of their bodies, something Durkacz says has never been done.

The patient pool is substantial, with about 3 million people living with MS worldwide and about 1 million in the United States. According to Grand View Research's multiple sclerosis therapeutics market projections, as cited by Durkacz, the category could exceed $38 billion by 2030.

Topline data is expected sometime in 2027, and the company says it is funded through 2027. Durkacz puts its market value at around $27 million, spread across three assets.

That's the tension. A tiny valuation against a large projected market suggests heavy binary risk is being priced in. Steady trial updates could shift sentiment, but the topline readout is the event that matters most.

The upside is a first-in-class treatment—one that could be used alongside existing immune therapies by a broad share of MS patients, if efficacy seen in a decade of animal models holds in humans.

The risk is just as real. Phase 2 can fail, timelines can slip, and a company this small has little cushion if it needs fresh capital beyond its current runway.

Protected Technology Could Decide Which AI Biotech Platforms Last

More AI-driven discovery likely means more biotech companies and more competition, which Durkacz welcomes because it puts more drugs into development.

For investors, the question shifts to protection. Is the platform patented? Can rivals copy it? Durkacz compares it to choosing between xAI's Grok and OpenAI's ChatGPT, where an edge can vanish quickly once a better model arrives.

Funded Phase 2 Programs With Clear Catalysts Offer the Cleanest Biotech Risk-Reward

Quantum BioPharma and Thermo Fisher Scientific sit at opposite ends of the same chain. The small developer carries the discovery risk on a single unmet need, while the established partner brings scale and trial experience to the execution side.

AI may widen the pipeline across biotech, but it doesn't shorten the trial phases that decide which stories become products.

The setup doesn't depend on AI headlines or a quick buyout. It depends on clean Phase 2 data, enough cash to reach it and a mechanism competitors can't easily copy.

Stay focused on Phase 2 data and cash runway, because that's what moves small-cap biotech stocks.

Investors who want a closer look can explore Quantum BioPharma's Phase 2 multiple sclerosis treatment research.